Steven A. Everett
Gründer bei MaveriX Oncology, Inc.
Profil
Steven A.
Everett was the founder of Cyterix Pharmaceuticals, Inc. (founded in 2010) where he held the title of Director, Chief Executive & Scientific Officer in 2011, and MaveriX Oncology, Inc. (founded in 2014) where he held the title of Chief Executive Officer & Director.
Dr. Everett's current job is as a Faculty Member at The University of California, San Francisco.
Dr. Everett's former job was as Head-Drug Discover & Translational Research at the University Of Dundee from 2005 to 2009.
Dr. Everett received an MBA from Brunel University and an undergraduate degree from the University of Ulster.
Dr. Everett is also the founder of Spear Therapeutics Ltd...
Aktive Positionen von Steven A. Everett
| Unternehmen | Position | Beginn |
|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | 09.06.2011 |
MaveriX Oncology, Inc.
 MaveriX Oncology, Inc. BiotechnologyHealth Technology MaveriX Oncology, Inc. operates as a a biotechnology company. It focuses on the discovery, development, and commercialization of targeted small molecule cancer chemo-immunotherapies. The company was founded by Steven A. Everett and Craig Alan Coburn in 2015 and is headquartered in Palo Alto, CA. | Gründer | 01.01.2014 |
Ehemalige bekannte Positionen von Steven A. Everett
| Unternehmen | Position | Ende |
|---|---|---|
| University Of Dundee | Corporate Officer/Principal | 01.01.2009 |
Spear Therapeutics Ltd.
 Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Gründer | - |
Cyterix Pharmaceuticals, Inc.
 Cyterix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyterix Pharmaceuticals, Inc. develops cancer therapeutics. It develops cancer therapeutics based on a proprietary OncoCY prodrug discovery approach. The company was founded by Paul R. Ortiz De Montellano, Luis Bayol and Steven A. Everett on April 10, 2010 and is headquartered in San Francisco, CA. | Vorstandsvorsitzender | - |
Ausbildung von Steven A. Everett
| University of Ulster | Undergraduate Degree |
| Brunel University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Spear Therapeutics Ltd.
Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Health Technology |
Cyterix Pharmaceuticals, Inc.
Cyterix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyterix Pharmaceuticals, Inc. develops cancer therapeutics. It develops cancer therapeutics based on a proprietary OncoCY prodrug discovery approach. The company was founded by Paul R. Ortiz De Montellano, Luis Bayol and Steven A. Everett on April 10, 2010 and is headquartered in San Francisco, CA. | Health Technology |
MaveriX Oncology, Inc.
MaveriX Oncology, Inc. BiotechnologyHealth Technology MaveriX Oncology, Inc. operates as a a biotechnology company. It focuses on the discovery, development, and commercialization of targeted small molecule cancer chemo-immunotherapies. The company was founded by Steven A. Everett and Craig Alan Coburn in 2015 and is headquartered in Palo Alto, CA. | Health Technology |